

Publication List Priv.-Doz. Dr. Mazda Adli (June 15, 2018)

Content:

- A. Original Papers (First or Senior Authorships)
- B. Co-Authorships
- C. Case Reports
- D. Reviews
- E. Comments
- F. Other Publications (not peer-reviewed)
- G. Editor
- H. Book Chapters

A. Major And Original Papers (First or Senior Authorships):

1.	Bauer M, Rush J, Ricken R, Pilhatsch M, <u>Adli M</u> (2018). Algorithms for treatment of major depressive disorder: efficacy and cost-effectiveness. <i>Pharmacopsychiatry</i> . Accepted on 7 June 2018.	IMPACT FACTOR 1.765
2.	Dimitrov A, Veer IM, Kleeblatt J, Seyfarth F, Roenneberg T, Ising M, Uhr M, Keck ME, Kramer A, Berger M, von Koch L, Walter H, <u>Adli M</u> (2018). Chronotype is associated with psychological well-being depending on the composition of the study sample. <i>J Health Psychol</i> . 2018 Jan 1:1359105317751618.	IMPACT FACTOR 2.182
3.	Ricken R, Wiethoff K, Reinhold T, Stamm TJ, Baghai TC, Fisher R, Seemüller F, Brieger P, Cordes J, Laux G, Hauth I, Möller HJ, Heinz A, Bauer M, <u>Adli M</u> (2018). A standardized stepwise drug treatment algorithm for depression reduces direct treatment costs in depressed inpatients - Results from the German Algorithm Project (GAP3). <i>J Affect Disord</i> . 228:173-177.	IMPACT FACTOR 3.432
4.	Ricken R, Busche M, Schlattmann P, Himmerich H, Bopp S, Bschor T, Richter C, Stamm TJ, Heinz A, Hellweg R, Lang UE, <u>Adli M</u> (2018). Cytokine serum levels remain unchanged during lithium augmentation of antidepressants in major depression. <i>J Psychiatr Res</i> . 96:203-208.	IMPACT FACTOR 4.183
5.	Ricken R, Bopp S, Schlattmann P, Himmerich H, Bschor T, Richter C, Elstner S, Stamm TJ, Schulz-Ratei B, Lingesleben A, Reischies FM, Sterzer P, Borgwardt S, Bauer M, Heinz A, Hellweg R, Lang UE, <u>Adli M</u> (2017). Ghrelin Serum Concentrations Are Associated with Treatment Response During Lithium Augmentation of Antidepressants. <i>Int J Neuropsychopharmacol</i> . 20(9):692-697.	IMPACT FACTOR 4.712
6.	<u>Adli M</u> , Wiethoff K, Baghai TC, Fisher R, Seemüller F, Laakmann G, Brieger P, Cordes J, Malevani J, Laux G, Hauth I, Möller HJ, Kronmüller KT, Smolka MN, Schlattmann P, Berger M, Ricken R, Stamm TJ, Heinz A, Bauer M (2017). How Effective Is Algorithm-Guided Treatment for Depressed Inpatients? Results from the Randomized Controlled Multicenter German Algorithm Project 3 Trial. <i>Int J Neuropsychopharmacol</i> . 20(9):721-730.	IMPACT FACTOR 4.712
7.	Ricken R, Bopp S, Schlattmann P, Himmerich H, Bschor T, Richter C, Stamm TJ, Bauer F, Heinz A, Hellweg R, Lang UE, <u>Adli M</u> (2016). Leptin serum concentrations are associated with weight gain during lithium augmentation. <i>Psychoneuroendocrinology</i> . 71:31-35.	IMPACT FACTOR 4.944
8.	Stamm TJ, Rampp C, Wiethoff K, Stingl J, Mössner R, O Malley G, Ricken R, Seemüller F, Keck M, Fisher R, Gaebel W, Maier W, Möller HJ, Bauer M, <u>Adli M</u> (2016). The FKBP5 polymorphism rs1360780 influences the effect of an algorithm-based antidepressant treatment and is associated with remission in patients with major depression. <i>J Psychopharmacol</i> . 30(1):40-7.	IMPACT FACTOR 3.898
9.	Köhler S, Wiethoff K, Ricken R, Stamm T, Baghai TC, Fisher R, Seemüller F, Brieger P, Cordes J, Malevani J, Laux G, Hauth I, Möller HJ, Zeiler J, Heinz	IMPACT FACTOR

	A, Bauer M, <u>Adli M</u> (2015). Characteristics and differences in treatment outcome of inpatients with chronic vs. episodic major depressive disorders. <i>J Affect Disord.</i> 173: 126-33.	3.71
10.	Stamm TJ, Becker D, Sondergeld LM, Wiethoff K, Hiemke C, O'Malley G, Ricken R, Bauer M, <u>Adli M</u> (2014). Prediction of antidepressant response to venlafaxine by a combination of early response assessment and therapeutic drug monitoring. <i>Pharmacopsychiatry.</i> 47(4-5): 174-9.	IMPACT FACTOR 2.168
11.	Stamm TJ, Stingl J, Wiethoff K, Ricken R, Heinz A, Bauer M, O'Malley G, <u>Adli M</u> (2013). Depression with psychotic features is influenced by the polymorphism of the serotonin transporter gene. <i>J Affect Disord.</i> 151: 605-610.	IMPACT FACTOR 3.383
12.	Ricken R*, <u>Adli M*</u> , Lange C, Krusche E, Stamm TJ, Gaus S, Koehler S, Nase S, Bschor T, Richter C, Steinacher B, Heinz A, Rapp MA, Borgwardt S, Hellweg R, Lang UE (2013). Brain-derived neurotrophic factor serum concentrations in acute depressive patients increase during lithium augmentation of antidepressants. <i>J Clin Psychopharmacol.</i> 33(6): 806-9.	IMPACT FACTOR 3.761
13.	Lange C, Zschucke E, Ising M, Uhr M, Bermpohl F, <u>Adli M</u> (2013). Evidence for a normal HPA axis response to psychosocial stress in patients remitted from depression. <i>Psychoneuroendocrinology.</i> 38(11): 2729-36.	IMPACT FACTOR 5.591
14.	Ricken R, Wiethoff K, Reinhold T, Schietsch K, Stamm T, Kiermeir J, Neu P, Heinz A, Bauer M, <u>Adli M</u> (2011). Algorithm-guided treatment of depression reduces treatment costs - Results from the randomized controlled German Algorithm Project (GAPII). <i>J Affect Disord.</i> 134:249-256.	IMPACT FACTOR 3.740
15.	Sterzer P, Hilgenfeldt T, Freudenberg P, <u>Adli M</u> (2011). Unconscious emotional information processing in patients with major depressive disorder. <i>Psychol Med.</i> 5: 1-10.	IMPACT FACTOR 5.012
16.	Wiethoff K, Bauer M, Baghai TC, Möller HJ, Fisher R, Hollinde D, Kiermeir J, Hauth I, Laux G, Cordes J, Marneros A, Kronmüller K, Zeiler J, <u>Adli M</u> (2010). Prevalence and treatment outcome in anxious versus nonanxious depression: results from the German Algorithm Project. <i>J Clin Psychiatry.</i> 71:1047-54.	IMPACT FACTOR 5.218
17.	<u>Adli M</u> , Bschor T, Bauer M, Lucka C, Lewitzka U, Ising M, Uhr M, Müller-Oerlinghausen B, Baethge C (2009). Long-term outcome after lithium augmentation in unipolar depression: focus on HPA system activity. <i>Neuropsychobiology.</i> 60: 23-30.	IMPACT FACTOR 1.752
18.	Bauer M, Pfennig A, Linden M, Smolka M, Neu P, <u>Adli M</u> (2009). Efficacy of an algorithm-guided treatment compared to treatment as usual: A randomized controlled study of inpatients with depression. <i>J Clin Psychopharmacology.</i> 29: 327-333.	IMPACT FACTOR 5.092
19.	Bauer M, Glenn T, Whybrow PC, Grof P, Rasgon N, Alda M, Marsh W, Sagduyu K, Schmid R, <u>Adli M</u> (2008). Changes in self-reported sleep duration predict mood changes in bipolar disorder. <i>Psychol Med.</i> 38: 1069-71.	IMPACT FACTOR 4.718
20.	<u>Adli M</u> , Wiethoff K, Pfennig A, Stamm T, Baethge C, Bauer M (2008). Olanzapine in the treatment of depression with psychotic features – a prospective open-label study. <i>Int J Psychiatry Clin Pract.</i> 12: 202-209.	IMPACT FACTOR 0.410
21.	Mahlberg R, Kienast T, Bschor T, <u>Adli M</u> (2008). Evaluation of time memory in acutely depressed patients, manic patients, and healthy controls using a time reproduction task. <i>Eur Psychiatry.</i> 23: 430-433.	IMPACT FACTOR 2.433
22.	<u>Adli M</u> , Pilhatsch M, Bauer M, Köberle U, Ricken R, Janssen G, Ulrich S, Bschor T (2008). Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression. <i>Pharmacopsychiatry</i> 41: 252-7.	IMPACT FACTOR 2.402
23.	<u>Adli M</u> , Hollinde D, Stamm T, Wiethoff K, Tsahuridu M, Kirchheiner J, Heinz	IMPACT

	A, Bauer M (2007). Response to lithium augmentation treatment in depression is associated with the glycogen synthase kinase 3-beta (GSK3-beta) - 50T/C single nucleotide polymorphism. <i>Biol Psychiatry</i> 62: 1295-1302.	FACTOR 8.672
24.	<u>Adli M</u> , Whybrow P, Grof P, Rasgon N, Gyulai L, Baethge C, Glenn T, Bauer M (2005). Use of polypharmacy and self-reported mood in outpatients with bipolar disorder. <i>Int J Psychiatry Clin Practice</i> 9: 251-256.	IMPACT FACTOR 0.410
25.	<u>Adli M</u> , Berghöfer A, Linden M, Helmchen H, Müller-Oerlinghausen B, Mackert A, Stamm T, Bauer M (2002). Effectiveness and feasibility of a standardized stepwise drug treatment algorithm for inpatients with depressive disorders – results of a two-year observational study. <i>J Clin Psychiatry</i> 63: 782-79.	IMPACT FACTOR 5.053

B. Co-Authorships:

26.	Schennach R, Obermeier M, Spellmann I, Seemüller F, Musil R, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Bauer M, <u>Adli M</u> , Zeiler J, Bender W, Kronmüller T, Ising M, Brieger P, Maier W, Lemke MR, Rütther E, Klingberg S, Gastpar M, Möller H, Riedel M (2018). Remission in schizophrenia - what are we measuring? Comparing the consensus remission criteria to a CGI-based definition of remission and to remission in major depression. <i>Schizophr Res</i> . Submitted on 12 May 2018.	IMPACT FACTOR 3.986
27.	Reinbold CS, Forstner AJ, Hecker J, Fullerton JM, Hoffmann P, Hou L, Heilbronner U, Degenhardt F, <u>Adli M</u> , Akiyama K, Akula N, Arda R, Arias B, Backlund L, Benabarre A, Bengesser S, Kumar Bhattacharjee A, Biernacka JM, Birner A, Marie-Claire C, Cervantes P, Chen G, Chen H, Chillotti C, Clark SR, Colom F, Cousins DA, Cruceanu C, Czerski PM, Dayer A, Etain B, Falkai P, Frisén L, Gard S, Garnham JS, Goes FS, Grof P, Gruber O, Hashimoto R, Hauser J, Herms S, Jamain S, Jiménez E, Kahn J, Kassem L, Kittel-Schneider S, Kliwicky S, König B, Kusumi I, Lackner N, Laje G, Landén M, Lavebratt C, Leboyer M, Leckband SG, López Jaramillo CA, MacQueen G, Manchia M, Martinsson L, Mattheisen M, McCarthy MJ, McElroy SL, Mitjans M, Mondimore FM, Monteleone P, Nievergelt CM, Ösby U, Ozaki N, Perlis RH, Pfennig A, Reich-Erkelenz D, Rouleau AG, Schofield PR, Schubert KO, Schweizer BW, Seemüller F, Severino G, Shekhtman T, Shilling PD, Shimoda K, Simhandl C, Slaney CM, Smoller JW, Squassina A, Stamm T, Stopkova P, Tighe SK, Tortorella A, Turecki G, Volkert J, Witt SH, Wright AJ, Young LT, Zandi P, Potash JB, DePaulo JR, Bauer M, Reininghaus E, Novák T, Aubry J, Maj M, Baune BT, Mitchell PB, Vieta E, Frye MA, Rybakowski JK, Kuo P, Kato T, Grigoriu-Serbanescu M, Reif A, Del Zompo M, Bellivier F, Schalling M, Wray N, Kelsoe JR, Alda M, McMahon FJ, Schulze TG, Rietschel M, Nöthen MM, Cichon S (2018). Analysis of the influence of microRNAs in Lithium Response in Bipolar Disorder. <i>Front. Psychiatry</i> . Accepted on 03 May 2018. In print.	IMPACT FACTOR 3.532
28.	Kalman et al. (2018). Investigating polygenic burden in age at disease onset in bipolar disorder: findings from an international multicentric study. <i>Bipolar Disord</i> . Accepted on 11 Apr 2018. In print.	IMPACT FACTOR 4.539
29.	Musil R, Seemüller F, Meyer S, Spellmann I, <u>Adli M</u> , Bauer M, Kronmüller KT, Brieger P, Laux G, Bender W, Heuser I, Fisher R, Gaebel W, Schennach R, Möller HJ, Riedel M (2018). Subtypes of depression and their overlap in a naturalistic inpatient sample of major depressive disorder. <i>Int J Methods Psychiatr Res</i> . 27(1).	IMPACT FACTOR 3.176
30.	International Consortium on Lithium Genetics (ConLi+Gen) (2018). Association of Polygenic Score for Schizophrenia and HLA Antigen and	IMPACT FACTOR

	Inflammation Genes With Response to Lithium in Bipolar Affective Disorder: A Genome-Wide Association Study. <i>JAMA Psychiatry</i> . 75(1):65-74.	15.307
31.	Haffner P, Quinlivan E, Fiebig J, Sondergeld LM, Strasser ES, <u>Adli M</u> , Moritz S, Stamm TJ (2018). Improving functional outcome in bipolar disorder: A pilot study on metacognitive training. <i>Clin Psychol Psychother</i> . 25(1):50-58.	IMPACT FACTOR 1.933
32.	Spellmann I, Schennach R, Seemüller F, Meyer S, Musil R, Jäger M, Schmauß M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Bauer M, <u>Adli M</u> , Zeiler J, Bender W, Kronmüller KT, Ising M, Brieger P, Maier W, Lemke MR, Rütther E, Klingberg S, Gastpar M, Riedel M, Möller HJ (2016). Validity of remission and recovery criteria for schizophrenia and major depression: comparison of the results of two one-year follow-up naturalistic studies. <i>Eur Arch Psychiatry Clin Neurosci</i> . 267(4):303-313.	IMPACT FACTOR 4.113
33.	Strasser ES, Haffner P, Fiebig J, Quinlivan E, <u>Adli M</u> , Stamm TJ (2016). Behavioral measures and self-report of impulsivity in bipolar disorder: no association between Stroop test and Barratt Impulsiveness Scale. <i>Int J Bipolar Disord</i> . 4(1):16.	IMPACT FACTOR 4.880
34.	The International Consortium on Lithium Genetics (ConLiGen)(2016). Genome-wide association study of 40,000 individuals identifies two novel loci associated with bipolar disorder. <i>Hum Mol Genet</i> . 25(15):3383-3394.	IMPACT FACTOR 5.985
35.	Seemüller F, Obermeier M, Schennach R, Bauer M, <u>Adli M</u> , Brieger P, Laux G, Riedel M, Falkai P, Möller HJ (2016). Stability of remission rates in a 3-year follow-up of naturalistic treated depressed inpatients. <i>BMC Psychiatry</i> . 16:153.	IMPACT FACTOR 2.210
36.	Hasselmann H, Bellmann-Strobl J, Ricken R, Oberwahrenbrock T, Rose M, Otte C, <u>Adli M</u> , Paul F, Brandt AU, Finke C, Gold SM (2016). Characterizing the phenotype of multiple sclerosis – associated depression in comparison with idiopathic major depression. <i>Mult Scler</i> . 22(11):1476-1484.	IMPACT FACTOR 4.82
37.	Hou L, Heilbronner U, Degenhardt F, <u>Adli M</u> , Akiyama K, Akula N, Arda R, Arias B, Backlund L, Banzato CEM, Benabarre A, Bengesser S, Bhattacharjee AK, Biernacka JM, Birner A, Brichant-Petitjean C, Bui ET, Cervantes P, Chen GB, Chen HC, Chillotti C, Cichon S, Clark SR, Colom F, Cousins DA, Cruceanu C, Czerski PM, Dantas CR, Dayer A, Étain B, Falkai P, Forstner AJ, Frisén L, Fullerton JM, Gard S, Garnham JS, Goes FS, Grof P, Gruber O, Hashimoto R, Hauser J, Herms S, Hoffmann P, Hofmann A, Jamain S, Jiménez E, Kahn JP, Kassem L, Kittel-Schneider S, Kliwicky S, König B, Kusumi I, Lackner N, Laje G, Landén M, Lavebratt C, Leboyer M, Leckband SG, Jaramillo CAL, MacQueen G, Manchia M, Martinsson L, Mattheisen M, McCarthy MJ, McElroy SL, Mitjans M, Mondimore FM, Monteleone P, Nievergelt CM, Nöthen MM, Ösby U, Ozaki N, Perlis RH, Pfennig A, Reich-Erkelenz D, Rouleau GA, Schofield PR, Schubert KO, Schweizer BW, Seemüller F, Severino G, Shekhtman T, Shilling PD, Shimoda K, Simhandl C, Slaney CM, Smoller JW, Squassina A, Stamm T, Stopkova P, Tighe SK, Tortorella A, Turecki G, Volkert J, Witt S, Wright A, Young LT, Zandi PP, Potash JB, DePaulo JR, Bauer M, Reininghaus EZ, Novák T, Aubry JM, Maj M, Baune BT, Mitchell PB, Vieta E, Frye MA, Rybakowski JK, Kuo PH, Kato T, Grigoriu-Serbanescu M, Reif A, Del Zompo M, Bellivier F, Schalling M, Wray NR, Kelsoe JR, Alda M, Rietschel M, McMahon FJ, Schulze TG (2016). Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. <i>Lancet</i> . 387(10023):1085-1093.	IMPACT FACTOR 39.207
38.	Bauer M, Berman S, Stamm T, Plotkin M, <u>Adli M</u> , Pilhatsch M, London ED, Helleman GS, Whybrow PC, Schlagenhaut F (2016). Levothyroxine effects on depressive symptoms and limbic glucose metabolism in bipolar disorder: a randomized, placebo-controlled positron emission tomography study. <i>Mol Psychiatry</i> . 21(2):229-36.	IMPACT FACTOR 5.620

39.	Willert A, Mohnke S, Erk S, Schnell K, Romanczuk-Seiferth N, Krusche E, Schreiter S, Spengler S, Herold D, Wackerhagen C, Pöhland L, Garbusow M, Stamm T, <u>Adli M</u> , Heinz A, Bempohl F, Walter H. (2015). Alterations in neural Theory of Mind processing in euthymic patients with bipolar disorder and unaffected relatives. <i>Bipolar Disorders</i> . 17(8):880-91	IMPACT FACTOR 4.888
40.	Seemüller F, Meier S, Obermeier M, Musil R, Bauer M, <u>Adli M</u> , Kronmüller K, Holsboer F, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Riedel M, Falkai P, Möller HJ (2014). Three-Year long-term outcome of 458 naturalistically treated inpatients with major depressive episode: severe relapse rates and risk factors. <i>Eur Arch Psychiatry Clin Neurosci</i> . 264(7): 567-75.	IMPACT FACTOR 3.355
41.	Stamm TJ, Lewitzka U, Sauer C, Pilhatsch M, Smolka MN, Koeberle U, <u>Adli M</u> , Ricken R, Scherk H, Frye MA, Juckel G, Assion HJ, Gitlin M, Whybrow PC, Bauer M (2014). Supraphysiologic doses of levothyroxine as adjunctive therapy in bipolar depression: a randomized, double-blind, placebo-controlled study. <i>J Clin Psychiatry</i> . 75(2): 162-8.	IMPACT FACTOR 3.761
42.	Rentzsch J, <u>Adli M</u> , Wiethoff K, Gómez-Carrillo de Castro A, Gallinat J (2014). Pretreatment anterior cingulate activity predicts antidepressant treatment response in major depressive episodes. <i>Eur Arch Psychiatry Clin Neurosci</i> . 264(3): 213-23.	IMPACT FACTOR 3.525
43.	Manchia M, <u>Adli M</u> , Akula N, Ardu R, Aubry JM, Backlund L, Banzato CE, Baune BT, Bellivier F, Bengesser S, Biernacka JM, Brichant-Petitjean C, Bui E, Calkin CV, Cheng AT, Chillotti C, Cichon S, Clark S, Czerski PM, Dantas C, Zompo MD, Depaulo JR, Detera-Wadleigh SD, Etain B, Falkai P, Frisé L, Frye MA, Fullerton J, Gard S, Garnham J, Goes FS, Grof P, Gruber O, Hashimoto R, Hauser J, Heilbronner U, Hoban R, Hou L, Jamain S, Kahn JP, Kassem L, Kato T, Kelsoe JR, Kittel-Schneider S, Kliwicki S, Kuo PH, Kusumi I, Laje G, Lavebratt C, Leboyer M, Leckband SG, López Jaramillo CA, Maj M, Malafosse A, Martinsson L, Masui T, Mitchell PB, Mondimore F, Monteleone P, Nallet A, Neuner M, Novák T, O'Donovan C, Osby U, Ozaki N, Perlis RH, Pfennig A, Potash JB, Reich-erkelenz D, Reif A, Reininghaus E, Richardson S, Rouleau GA, Rybakowski JK, Schalling M, Schofield PR, Schubert OK, Schweizer B, Seemüller F, Grigoriou-Serbanescu M, Severino G, Seymour LR, Slaney C, Smoller JW, Squassina A, Stamm T, Steele J, Stopkova P, Tighe SK, Tortorella A, Turecki G, Wray NR, Wright A, Zandi PP, Zilles D, Bauer M, Rietschel M, McMahon FJ, Schulze TG, Alda M (2013). Assessment of Response to Lithium Maintenance Treatment in Bipolar Disorder: A Consortium on Lithium Genetics (ConLiGen) Report. <i>PLoS One</i> . 8(6):e65636	IMPACT FACTOR 3.530
44.	Berghöfer A, Alda M, <u>Adli M</u> , Baethge C, Bauer M, Bschor T, Grof P, Müller-Oerlinghausen B, Rybakowski JK, Suwalska A, Pfennig A (2013). Stability of lithium treatment in bipolar disorder - long-term follow-up of 346 patients. <i>Int J Bipolar Disord</i> . 1:11.	
45.	Rhein C, Naumann J, Mühle C, Zill P, <u>Adli M</u> , Hegerl U, Hiemke C, Mergl R, Möller HJ, Reichel M, Kornhuber J (2013). The Acid Sphingomyelinase Sequence Variant p.A487V Is Not Associated With Decreased Levels of Enzymatic Activity. <i>JIMD Rep</i> . 8:1-6	IMPACT FACTOR 4.138
46.	Musil R, Zill P, Seemüller F, Bondy B, Meyer S, Spellmann I, Bender W, <u>Adli M</u> , Heuser I, Fisher R, Gaebel W, Maier W, Rietschel M, Rujescu D, Schennach R, Möller HJ, Riedel M (2013). Genetics of emergent suicidality during antidepressive treatment--data from a naturalistic study on a large sample of inpatients with a major depressive episode. <i>Eur Neuropsychopharmacol</i> . 23(7): 663-74.	IMPACT FACTOR 4.736
47.	Musil R, Zill P, Seemüller F, Bondy B, Obermeier M, Spellmann I, Bender W, <u>Adli M</u> , Heuser I, Zeiler J, Gaebel W, Maier W, Rietschel M, Rujescu D, Schennach R, Möller HJ, Riedel M (2013). No influence of brain-derived	IMPACT FACTOR 3.355

	neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depression. <i>Eur Arch Psychiatry Clin Neurosci.</i> 263(5):405-12.	
48.	Lange C, <u>Adli M</u> , Zschucke E, Beyer R, Ising M, Uhr M, BERPPOHL F (2012). Affective set-shifting deficits in patients with major depression in remission. <i>J Psychiatr Res.</i> 46(12):1623-6.	IMPACT FACTOR 4.460
49.	Stoy M, Schlagenhauf F, Sterzer P, BERPPOHL F, Hägele C, Suchotzki K, Schmack K, Wrase J, Ricken R, Knutson B, Adli M, Bauer M, Heinz A, Ströhle A (2012). Hyporeactivity of ventral striatum towards incentive stimuli in unmedicated depressed patients normalizes after treatment with escitalopram. <i>J Psychopharmacol.</i> 26:677-688.	IMPACT FACTOR 3.396
50.	Ricken R, BERPPOHL F, Schlattmann P, Bschor T, Adli M, Mönter N, Bauer M (2012). Long-term treatment with supraphysiological doses of thyroid hormone in affective disorders - effects on bone mineral density. <i>J Affect Disord.</i> 136: 89-94.	IMPACT FACTOR 3.740
51.	Seemüller F, Riedel M, Obermeier M, Schennach-Wolff R, Spellmann I, Meyer S, Bauer M, Adli M, Kronmüller K, Ising M, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Möller HJ (2012). The validity of self-rated psychotic symptoms in depressed inpatients. <i>Eur Psychiatry.</i> 27(7): 547-52.	IMPACT FACTOR 3.08
52.	Riedel M, Möller HJ, Obermeier M, Adli M, Bauer M, Kronmüller K, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Schennach-Wolff R, Henkel V, Seemüller F (2011). Clinical predictors of response and remission in inpatients with depressive syndromes. <i>J Affect Disord.</i> 133:137-49.	IMPACT FACTOR 3.383
53.	Henkel V, Seemüller F, Obermeier M, <u>Adli M</u> , Bauer M, Kronmüller K, Holsboer F, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Mayr A, Riedel M, Möller HJ (2011). Relationship between baseline severity and antidepressant treatment outcome. <i>Pharmacopsychiatry.</i> 44(1): 27-32.	IMPACT FACTOR 2.317
54.	Riedel M, Möller HJ, Obermeier M, Schennach-Wolff R, Bauer M, <u>Adli M</u> , Kronmüller K, Nickel T, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Seemüller F (2010). Response and remission criteria in major depression – a validation of current practice. <i>J Psychiatr Res</i> 44: 1063-1068.	IMPACT FACTOR 4.679
55.	Seemüller F, Möller HJ, Obermeier M, <u>Adli M</u> , Bauer M, Kronmüller K, Holsboer F, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Schennach-Wolff R, Henkel V, Riedel M (2010). Do efficacy and effectiveness samples differ in antidepressant treatment outcome? an analysis of eligibility criteria in randomized controlled trials. <i>J Clin Psychiatry.</i> 71:1425-33.	IMPACT FACTOR 5.218
56.	Seemüller F, Riedel M, Obermeier M, Bauer M, <u>Adli M</u> , Kronmüller K, Holsboer F, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Dichgans E, Bottländer R, Musil R, Möller HJ (2010). Outcomes of 1014 naturalistically treated inpatients with major depressive episode. <i>Eur Neuropsychopharmacol</i> 20 :346-55.	IMPACT FACTOR 3.661
57.	BERPPOHL F, Kahnt T, Dalanay U, Hägele C, Sajonz B, Wegner T, Stoy M, <u>Adli M</u> , Krüger S, Wrase J, Ströhle A, Bauer M, Heinz A (2010). Altered representation of expected value in the orbitofrontal cortex in mania. <i>Hum Brain Mapp.</i> 31: 958-69.	IMPACT FACTOR 5.395
58.	Abou Jamra R, Schulze TG, Becker T, Brockschmidt FF, Green E, Alblas MA, Wendland JR, <u>Adli M</u> , Grozeva D, Strohmeier J, Georgi A, Craddock N, Propping P, Rietschel M, Nöthen MM, Cichon S, Schumacher J (2010). A systematic association mapping on chromosome 6q in bipolar affective disorder-evidence for the melanin-concentrating-hormone-receptor-2 gene as a risk factor for bipolar affective disorder. <i>Am J Med Genet B Neuropsychiatr Genet.</i> 153B: 878-84.	IMPACT FACTOR 3.932
59.	BERPPOHL F, Walter M, Sajonz B, Lücke C, Hägele C, Sterzer P, <u>Adli M</u> , Heinz A, Northoff G (2009). Attentional modulation of emotional stimulus	IMPACT FACTOR

	processing in patients with major depression—Alterations in prefrontal cortical regions. <i>Neuroscience Letters</i> . 463: 108-113.	2.200
60.	Seemüller F, Riedel M, Obermeier M, Bauer M, <u>Adli M</u> , Mundt C, Holsboer F, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Jäger M, Henkel V, Möller HJ (2009). The controversial link between antidepressants and suicidality risks in adults: data from a naturalistic study on a large sample of in-patients with a major depressive episode. <i>Int J Neuropsychopharmacol</i> . 12(2):181-9.	IMPACT FACTOR 4.378
61.	Bermpohl F, Dalanay U, Kahnt T, Sajonz B, Heimann H, Ricken R, Stoy M, Hägele C, Schlagenhaut F, <u>Adli M</u> , Wrase J, Ströhle A, Heinz A, Bauer M (2009). A preliminary study of increased amygdala activation to positive affective stimuli in mania. <i>Bipolar Disord</i> . 11: 70-75.	IMPACT FACTOR 3.959
62.	Bauer M, Glenn T, Grof P, Rasgon N, Alda M, Marsh W, Sagduyu K, Schmid R, <u>Adli M</u> , Whybrow PC (2009). Comparison of Sleep/Wake Parameters for Self-Monitoring Bipolar Disorder. <i>J Affect Disord</i> . 116: 170-175.	IMPACT FACTOR 3.271
63.	Henkel V, Seemüller F, Obermeier M, <u>Adli M</u> , Bauer M, Mundt C, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Mayr A, Möller HJ, Riedel M (2009). Does early improvement triggered by antidepressants predict response/remission? - Analysis of data from a naturalistic study on a large sample of inpatients with major depression. <i>J Affect Disord</i> . 115: 439-449.	IMPACT FACTOR 3.271
64.	Mahlberg R, <u>Adli M</u> , Bschor T, Kienast T (2008). Age effects on trail making test during acute depressive and manic episode. <i>Int J Neurosci</i> . 118: 1347-1356.	IMPACT FACTOR 0.884
65.	Berghöfer A, Alda M, <u>Adli M</u> , Baethge C, Bauer M, Bschor T, Glenn T, Grof P, Müller-Oerlinghausen B, Rybakowski J, Suwalska A, Pfennig A (2008). Long-term effectiveness of lithium in bipolar disorder – a multicenter investigation of patients with typical and atypical features. <i>J Clin Psychiatry</i> 69(12):1860-8.	IMPACT FACTOR 5.053
66.	Seemüller F, Riedel M, Wickelmaier F, <u>Adli M</u> , Mundt C, Marneros A, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Jäger M, Möller HJ, Henkel V (2008). Atypical symptoms in hospitalised patients with major depressive episode: frequency, clinical characteristics, and internal validity. <i>J Affect Disord</i> . 108 (3): 271-278.	IMPACT FACTOR 3.271
67.	Stamm TJ, <u>Adli M</u> , Kirchheiner J, Smolka MN, Kaiser R, Tremblay P, Bauer M (2008). Serotonin transporter gene and lithium augmentation response in depression. <i>Psychiatr Genetics</i> . 18: 92-97.	IMPACT FACTOR 2.696
68.	Bauer M, Blumentritt H, Finke R, Schlattmann P, <u>Adli M</u> , Baethge C, Bschor T, Müller-Oerlinghausen B, Berghöfer A (2007). Using ultrasonographically to determine thyroid size and prevalence of goiter in lithium-treated patients with affective disorders. <i>J Affect Disord</i> 104: 45-51.	IMPACT FACTOR 3.271
69.	Knubben K, Reischies FM, <u>Adli M</u> , Schlattmann P, Bauer M, Dimeo F (2007). A randomized, controlled study on the effects of a short-term endurance training programme in patients with major depression. <i>Br J Sports Med</i> 41(1):29-33.	IMPACT FACTOR 2.126
70.	Baethge C, Blumentritt H, Berghöfer A, Bschor T, Glenn T, <u>Adli M</u> , Schlattmann P, Bauer M (2005). Long-term lithium treatment and thyroid antibodies – a study of 100 patients with affective disorders and 100 normal controls. <i>J Psychiatry Neurosci</i> 30: 423-42.	IMPACT FACTOR 4.123
71.	Baethge C, Baldessarini RJ, Mathiske-Schmidt K, Hennen J, Berghöfer A, Müller-Oerlinghausen B, Bschor T, <u>Adli M</u> , Bauer M (2005). Long-term combination versus monotherapy with lithium and carbamazepine in 46 bipolar I patients. <i>J Clin Psychiatry</i> . 66:174-182.	IMPACT FACTOR 5.053
72.	Bschor T, Baethge C, <u>Adli M</u> , Eichmann U, Ising M, Uhr M, Modell S, Künzel H, Müller-Oerlinghausen B, Bauer M (2003). Association between response to lithium augmentation and the combined DEX/CRH test in major	IMPACT FACTOR 4.679

	depressive disorder. <i>J Psychiatr Res</i> 37:135-143.	
73.	Bschor T, Baethge C, <u>Adli M</u> , Eichmann U, Ising M, Uhr M, Müller-Oerlinghausen B, Bauer M (2003). Lithium augmentation increases post-dexamethasone cortisol in the dexamethasone suppression test in unipolar major depression. <i>Depress Anxiety</i> . 17:43-48	IMPACT FACTOR 2.526
74.	Bschor T, Baethge C, <u>Adli M</u> , Lewitzka U, Eichmann U, Bauer M (2003). Hypothalamic-pituitary-thyroid system activity during lithium augmentation therapy in patients with unipolar major depression. <i>J Psychiatry Neurosci</i> 28: 210-216.	IMPACT FACTOR 4.123
75.	Bauer M, Berghöfer A, Bschor T, Baumgartner A, Kießlinger U, Hellweg R, <u>Adli M</u> , Baethge C, Müller-Oerlinghausen B (2002). Supraphysiological doses of L-thyroxine in the maintenance treatment of prophylaxis-resistant affective disorders. <i>Neuropsychopharmacology</i> . 27: 620-628.	IMPACT FACTOR 6.835
76.	Bschor T, <u>Adli M</u> , Baethge C, Eichmann U, Ising M, Uhr M, Modell S, Künzel H, Müller-Oerlinghausen B, Bauer M (2002). Lithium augmentation increases the ACTH and cortisol response in the combined DEX/CRH test in unipolar major depression. <i>Neuropsychopharmacology</i> 27: 470-478.	IMPACT FACTOR 6.835
77.	Bschor T, Berghöfer A, Ströhle A, Kunz D, <u>Adli M</u> , Müller-Oerlinghausen B, Bauer M (2002). How long should the lithium augmentation strategy be maintained? A 1-year follow up of a placebo-controlled study in unipolar refractory major depression. <i>J Clin Psychopharmacol</i> 22: 427-430.	IMPACT FACTOR 4.371

C. Case Reports:

78.	Pilhatsch MK, Burghardt R, Wandinger KP, Bauer M, <u>Adli M</u> (2006). Augmentation with atomoxetine in treatment-resistant depression with psychotic features. A case report. <i>Pharmacopsychiatry</i> 39(2): 79-80.	IMPACT FACTOR 2.402
79.	<u>Adli M</u> , Rossius W, Bauer M (1999). Olanzapine in the treatment of depressive disorders with psychotic symptoms. <i>Nervenarzt</i> . 70: 68-71.	IMPACT FACTOR 0.814

C. Reviews:

80.	Ricken R, Ulrich S, Schlattmann P, <u>Adli M</u> (2017). Tranylcypromine in mind (Part II): Review of clinical pharmacology and meta-analysis of controlled studies in depression. <i>Eur Neuropsychopharmacol</i> . 27(8):714-731.	IMPACT FACTOR 4.577
81.	Ulrich S, Ricken R, <u>Adli M</u> (2017). Tranylcypromine in mind (Part I): Review of pharmacology. <i>Eur Neuropsychopharmacol</i> . 27(8):697-713.	IMPACT FACTOR 4.577
82.	Holzinger F, Fahrenkrog S, Roll S, Kleefeld F, <u>Adli M</u> , Heintze C (2017). Discharge management strategies and post-discharge care interventions for depression - Systematic review and meta-analysis. <i>J Affect Disord</i> . 223:82-94.	IMPACT FACTOR 3.845
83.	Köhler S, Cierpinsky K, Kronenberg G, <u>Adli M</u> (2016). The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants. <i>J Psychopharmacol</i> . 30(1):13-22.	IMPACT FACTOR 3.898
84.	Borgmann M, Holtkamp M, <u>Adli M</u> , Behr J (2016). Depression and epilepsy: Two clinical pictures with common causes? <i>Nervenarzt</i> . 87(7):724-30.	IMPACT FACTOR 0.787
85.	Bauer M, <u>Adli M</u> , Ricken R, Severus E, Pilhatsch M (2014). Role of lithium augmentation in the management of major depressive disorder. <i>CNS Drugs</i> . 28(4): 331-42.	IMPACT FACTOR 4.376
86.	Bschor T, Bauer M, <u>Adli M</u> (2014). Chronic and treatment resistant depression — diagnosis and stepwise therapy. <i>Dtsch Arztebl Int</i> . 111(45):	IMPACT FACTOR

	766-76.	3.608
87.	Krings-Ernst I, Ulrich S, <u>Adli M</u> (2013). Antidepressant treatment with MAO-inhibitors during general and regional anesthesia: a review and case report of spinal anesthesia for lower extremity surgery without discontinuation of tranylcypromine. <i>Int J Clin Pharmacol Ther.</i> 51(10): 763-70.	IMPACT FACTOR 1.200
88.	Köhler S, Bauer M, <u>Adli M</u> (2012). Behandlungsstrategien der therapieresistenten Depression. <i>Psychiatrie und Psychotherapie up2date.</i> 6: 137-148.	
89.	Rentzsch, J, Ricken R, <u>Adli M</u> (2011). Akutbehandlung der Manie. <i>Psychiatrie und Psychotherapie up2date.</i> 5: 209-224.	
90.	Bauer M, <u>Adli M</u> , Bschor T, Pilhatsch M, Pfennig A, Sasse J, Lewitzka U (2010). Lithium's emerging role in the treatment of refractory major depressive episodes: augmentation of antidepressants. <i>Neuropsychobiology.</i> 62: 36-42.	IMPACT FACTOR 1.752
91.	Mazurek B, Olze H, Haupt H, Klapp BF, <u>Adli M</u> , Gross J, Szczepek AJ. (2010). Molecular biological aspects of neuroplasticity: approaches for treating tinnitus and hearing disorders. <i>HNO.</i> 58: 973-982.	IMPACT FACTOR 0.570
92.	Mazurek B, Stöver T, Haupt H, Klapp BF, <u>Adli M</u> , Gross J, Szczepek AJ (2010). The significance of stress: its role in the auditory system and the pathogenesis of tinnitus. <i>HNO.</i> 58(2):162-72.	IMPACT FACTOR 0.570
93.	Wiethoff K, Ricken R, Keck M, Baghai T, Bauer M, Möller H, <u>Adli M</u> (2009). Das Berliner Algorithmusprojekt. <i>Nervenheilkunde.</i> 4: 179-185.	IMPACT FACTOR 0.373
94.	Riedel M, Seemüller F, Wickelmaier F, Schennach-Wolff R, <u>Adli M</u> , Bauer M, Kranmüller K, Brieger P, Laux G, Bender W, Haeuser I, Zeiler J, Gaebel W, Jaeger M, Moeller H, Henkel V (2009). Häufigkeit und klinische Charakteristika von atypisch depressiven Symptomen. <i>Nervenheilkunde.</i> 4: 193-199.	IMPACT FACTOR 0.373
95.	Bschor T, <u>Adli M</u> (2008). Therapie depressiver Erkrankungen. Zertifizierte medizinische Fortbildung. <i>Dtsch Arztebl.</i> 105: 782–792.	IMPACT FACTOR 1.099
96.	<u>Adli M</u> , Bauer M, Rush AJ (2006). Algorithms and collaborative care systems for depression: are they effective and why? <i>Biol Psychiatry.</i> 59: 1029-1038.	IMPACT FACTOR 8.672
97.	Wiethoff K, Baghai T, Heinz A, Bauer M, <u>Adli M</u> (2005). Algorithmusgestützte Behandlung depressiver Erkrankungen: Was bringen systematische Therapieansätze im klinischen Alltag? <i>Med Welt.</i> 56: 332-337.	
98.	<u>Adli M</u> , Baethge C, Langlitz N, Bauer M (2005). Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? – a systematic review. <i>Eur Arch Psychiatry Clin Neurosci.</i> 255: 387-400.	IMPACT FACTOR 2.852
99.	Wiethoff K, Bauer M, Baghai T, Heinz A, <u>Adli M</u> (2005). Therapiealgorithmen in der Depressionsbehandlung - Das Berliner Algorithmusprojekt. <i>Nervenheilkunde</i> 24: 381-387.	IMPACT FACTOR 0.373
100.	Möller HJ, <u>Adli M</u> , Laux G, Müller N, Schmitt J, unter Mitwirkung einer Expertengruppe „Kognitive Störungen bei Antidepressivabehandlung“ (2004). Kognitive und psychomotorische Effekte von Antidepressiva unter besonderer Berücksichtigung von SSRIs. <i>Psychopharmakotherapie.</i> 1: 15-21.	IMPACT FACTOR 0.202
101.	Gruebner O, Rapp MA, <u>Adli M</u> , Kluge U, Galea S, Heinz A (2017). Cities and Mental Health. <i>Dtsch Arztebl Int.</i> 114(8):121-127.	IMPACT FACTOR 3.738
102.	<u>Adli M</u> , Rush AJ, Möller H-J, Bauer M (2003). Algorithms for optimizing the treatment of depression: making the right decision at the right time. <i>Pharmacopsychiatry.</i> 36 [suppl 3]: 222-229.	IMPACT FACTOR 2.402

103.	Bschor T, Lewitzka U, Sasse J, <u>Adli M</u> , Koberle U, Bauer M (2003). Lithium augmentation in treatment-resistant depression: clinical evidence, serotonergic and endocrine mechanisms. <i>Pharmacopsychiatry</i> 36 [suppl 3]: 230-234.	IMPACT FACTOR 2.402
104.	Bauer M, <u>Adli M</u> , Baethge C, Berghöfer A, Sasse J, Heinz A, Bschor T (2003). Lithium augmentation therapy in refractory depression: clinical evidence and neurobiological mechanisms. <i>Can J Psychiatry</i> . 48: 440-448	IMPACT FACTOR 2.828
105.	Bauer M, <u>Adli M</u> , Bschor T, Heinz A, Rasgon N, Frye M, Grunze H, Kupka R, Whybrow PC (2003). Clinical applications of levothyroxine in refractory mood disorders. <i>Clin Appr Bipol Disord</i> . 2: 49-56.	IMPACT FACTOR 2.531
106.	Bauer M, Forsthoff A, Baethge C, <u>Adli M</u> , Berghöfer A, Döpfmer S, Bschor T (2003). Lithium augmentation therapy in refractory depression – update 2002. <i>Eur Arch Psychiatry Clin Neurosci</i> 253: 132-139.	IMPACT FACTOR 2.852
107.	Bschor T, Lewitzka U, Sasse J, <u>Adli M</u> , Koberle U & Bauer M (2003). Lithium augmentation in treatment-resistant depression: clinical evidence, serotonergic and endocrine mechanisms. <i>Pharmacopsychiatry</i> . 36 (Suppl 3): 230-234.	IMPACT FACTOR 2.402
108.	<u>Adli M</u> , Bschor T, Canata B, Döpfmer S, Bauer M (1998). Lithium in der Behandlung der akuten Depression. <i>Fortschr Neurol Psychiat</i> 66: 435-441	IMPACT FACTOR 0.793

E. Comments and Letters:

109.	<u>Adli M</u> , Berger M, Brakemeier EL, Engel L, Fingerhut J, Gomez-Carrillo A, Hehl R, Heinz A, H JM, Mehran N, Tolaas S, Walter H, Weiland U, Stollmann J (2017). Neurourbanism: towards a new discipline. <i>Lancet Psychiatry</i> . 4(3):183-185.	IMPACT FACTOR 11.588
110.	<u>Adli M</u> , Berger M (2015). Tricyclic antidepressants for initial treatment of depressive episodes? <i>Con. Nervenarzt</i> . 87(5):561-2.	IMPACT FACTOR 0.787
111.	Berger M, <u>Adli M</u> , Beine KH, Bschor T, Herpertz S, Lauterbach K (2015). Psychiatrische Versorgung: Das Krankenhaus-Psych-Budget – ein Alternativkonzept. <i>Dtsch Arztebl</i> . 112(13): A 574-6.	IMPACT FACTOR 3.608
112.	Bschor T, Bauer M, <u>Adli M</u> (2015). Comment on: Chronic and treatment resistant depression: diagnosis and stepwise therapy. <i>Dtsch Arztebl Int</i> . 112(24):421-2.	IMPACT FACTOR 3.608
113.	<u>Adli M</u> , Hegerl U. (2014). Do we underestimate the benefits of antidepressant drugs? <i>Lancet</i> . 383(9926): 1361-2.	IMPACT FACTOR 39.207
114.	Fakhri H*, Ricken R*, <u>Adli M*</u> , Fajol A, Walter M, Föller M, Lang F, Lang UE, Lange C (2014). Impact of Lithium Treatment on FGF-23 Serum Concentrations in Depressive Patients. <i>J Clin Psychopharmacol</i> . 34(6): 745-7.	IMPACT FACTOR 3.761
115.	<u>Adli M</u> , Kleinert S, Bonk M, Wesslingh S, Ganten D (2011). From science to policy: the M8 Alliance invites policy makers to step in. <i>Lancet</i> , 378: 1447-1449.	IMPACT FACTOR 30.758
116.	Schulze G, Alda M, <u>Adli M</u> , Akula N, Ardaur R, Chilotti C, Cichon S, Czerski P, Del Zompo M, Detera-Wadleigh S, Grof P, Gruber O, Hashimoto R, Hauser J, Hoban R, Iwata N, Kassem L, Kato T, Kittel-Schneider S, Kliwicki S, Kelsoe J, Kusumi I, Laje G, Leckband S, Manchia M, MacQueen G, Masui T, Ozaki N, Perlis R, Pfennig A, Piccardi P, Richardson S, Rouleau G, reif A, Rybakowski J, Sasse J, Schumacher J, Severino G, Smoller J, Squassina A, Turecki G, Young L, Yoshikawa T, Bauer M, MacMahon F (2010). The international Consortium on Lithium Genetics (ConLiGen) – an initiative by	IMPACT FACTOR 1.752

	the NIMH and IGSLI to study the genetic basis of response to lithium treatment. <i>Neuropsychobiology</i> 62: 72-78.	
117.	<u>Adli M</u> , Kleinert S, Lafont, A, Kahn A, Ganten D (2009). Shaping future health: Berlin Evolution of Medicine Summit. <i>Lancet</i> . 373: 519-520.	IMPACT FACTOR 30.758
118.	Grunze H, <u>Adli M</u> , Bauer M, Berger M, Bergmann A, Bräunig P, Bschor T, Falkai P, Gastpar M, Greil W, Kasper S, Krüger S, Laux G, Müller WE, Naber D, Walden J (2007). Clinical standing of valproate treatment of bipolar disorders. <i>Fortschr Neurol Psychiatr</i> . 75(4): 220-235.	IMPACT FACTOR 0.793
119.	Bauer M, <u>Adli M</u> , Bschor T, Döpfmer S (1999). Stellungnahme. <i>Fortschr Neurol Psychiatr</i> 67: 386.	IMPACT FACTOR 0.793

F. Other Publications (not peer-reviewed):

120.	<u>Adli M</u> , Berger M, Brakemeier EL, Engel L, Fingerhut J, Hehl R, Heinz A, Mayer H. J, Matussek T, Mehran N, Tolaas S, Walter H, Weiland U, Sollmann J (2016). Neurourbanistik – ein methodischer Schulterschluss zwischen Stadtplanung und Neurowissenschaften. <i>Die Psychiatrie</i> . 13(2):70-8.	
121.	Kiermeir J, Gassner LM, Siebörger A, Wiethoff K, Ricken R, Stamm T, Bauer M, Heinz A, <u>Adli M</u> (2012). Euthymic Therapy to Reduce Residual Symptoms of Depression and Strengthen Self-Care: a Randomised Controlled Trial. <i>German J Psychiatry</i> . 15 (1): 15-22.	
122.	Lange C, <u>Adli M</u> (2010). Residualsymptome nach akuter Depression. <i>MMW Fortschr Med</i> . 152(3), 34-35.	
123.	Heimann H, Dietz F, Lange C, <u>Adli M</u> (2009). Behandlung von depressiven Episoden – Relevanz der Vollremission. <i>Neuro aktuell</i> . 2: 31-33.	
124.	Bauer M, Pfennig A, Wiethoff K, Sasse J, Ricken R, Pilhatsch M, <u>Adli M</u> (2006). Warum ist die Remission ein wichtiges Ziel in der Depressionsbehandlung? <i>PsychoNeuro</i> . 32: 67-71.	
125.	Bauer M, Köberle U, Sasse J, Gutzmann C, Neuhaus K, <u>Adli M</u> , Pfennig A, Heinz A (2005). Rezidivprophylaxe Bipolarer Erkrankungen - auf was es ankommt. <i>Schweizer Zeitschrift für Psychiatrie & Neurologie</i> . 1: 37-44.	
126.	<u>Adli M</u> (2005). Bipolarer Alkoholiker: mit Valproinsäure zwei Fliegen mit einer Klappe schlagen? <i>Info Neurologie Psychiatrie</i> . 7 [suppl1]: 12-13.	
127.	Bauer M, Stamm T, Sasse J, <u>Adli M</u> (2005). Duloxetine – a novel dual acting antidepressant [Duloxetine - ein neues Antidepressivum mit dualem Wirkmechanismus]. <i>Die Psychiatrie</i> 2: 244-251.	
128.	Pfennig A, <u>Adli M</u> , Bauer M (2004). Atypische Neuroleptika bei wahnhafter Depression. <i>Info Neurologie Psychiatrie</i> 6 [suppl1]: 36–37.	
129.	<u>Adli M</u> (2004). Die „maskierte“ bipolare Störung: Fehldiagnose unipolare Depression vermeiden. <i>Der Neurologe & Psychiater</i> . 3: 38-42.	
130.	Sasse J, Köberle U, Bschor T, <u>Adli M</u> , Trendelenburg M, Bauer M. (2003). Bipolare Depression: L-Thyroxin-Augmentation als Möglichkeit einer medikamentösen Behandlung. <i>PsychoNeuro</i> . 29: 400-402.	
131.	<u>Adli M</u> , Bauer M (2003). Wahnhafte Depression – eine vernachlässigte Sonderform. (Neuroleptika bei wahnhafter Depression). <i>Info Neurologie Psychiatrie</i> . 2: 44-50.	

G. Editor

<u>Adli M</u> . Stress and the City: Warum Städte uns krank machen. Und warum sie trotzdem gut für uns sind. 1. Auflage, 2017, C. Bertelsmann Verlag, München

Bauer M, Berghöfer A, Adli M (eds.) Akute und therapieresistente Depressionen. Pharmakotherapie, Psychotherapie, Innovationen. 2., vollständig neuberarbeitete Auflage 2005 (1. Auflage 1997, 1. Nachdruck 1998). Springer Verlag, Berlin, Heidelberg, New York

I. Book Chapters

Schramm E, Bauer M, Adli M, (2017). Chronische und therapieresistente Depressionen. In: Voderholzer U, Hohagen F (Hrsg.). Therapie psychischer Erkrankungen: State of the Art. 13. Auflage. München: Urban & Fischer S. 183-208.

Schramm E, Bauer M, Adli M, (2016). Chronische und therapieresistente Depressionen. In: Voderholzer U, Hohagen F (Hrsg.). Therapie psychischer Erkrankungen: State of the Art. 12. Auflage. München: Urban & Fischer S. 183-208.

Schramm E, Bauer M, Adli M, (2015). Chronische und therapieresistente Depressionen. In: Voderholzer U, Hohagen F (Hrsg.). Therapie psychischer Erkrankungen: State of the Art. 11. Auflage. München: Urban & Fischer S. 183-208.

Schramm E, Bauer M, Adli M, (2014). Chronische und therapieresistente Depressionen. In: Voderholzer U, Hohagen F (Hrsg.). Therapie psychischer Erkrankungen: State of the Art. 10. Auflage. München: Urban & Fischer S. 183-208.

Schramm E, Bauer M, Adli M, (2013). Chronische und therapieresistente Depressionen. In: Voderholzer U, Hohagen F (Hrsg.). Therapie psychischer Erkrankungen: State of the Art. 9. Auflage. München: Urban & Fischer S. 183-208.

Schramm E, Bauer M, Adli M, (2012). Chronische und therapieresistente Depressionen. In: Voderholzer U, Hohagen F (Hrsg.). Therapie psychischer Erkrankungen: State of the Art. 8. Auflage. München: Urban & Fischer

Schramm E, Bauer M, Adli M, (2011). Chronische und therapieresistente Depressionen. In: Voderholzer U, Hohagen F (Hrsg.). Therapie psychischer Erkrankungen: State of the Art. 7. Auflage. München: Urban & Fischer S. 165-188

Pfennig A, Adli M (2008). Antidepressiva-Hochdosisbehandlung. In: Bschor T (Hrsg.) Behandlungsmanual therapieresistente Depression. Stuttgart: Kohlhammer, S. 40-47.

Wiethoff K, Adli M (2008). Systematisierte Therapiealgorithmen (antidepressive Stufenpläne). In: Bschor T (Hrsg.) Behandlungsmanual therapieresistente Depression. Stuttgart: Kohlhammer, S. 408-418

Bschor T, Lewitzka, Adli M (2006). Lithium in non-psychiatric conditions. In: Bauer, Grof, Müller-Oerlinghausen (Hrsg.) Bauer M, Grof P, Müller-Oerlinghausen (Eds.) Lithium in Neuropsychiatry – The Comprehensive Guide. Taylor and Francis Books, Abingdon, S. 237-250

Bauer M, Pfennig A, Mavrogiorgou P, Juckel G, Adli M, Sasse J, Heinz A (2005) Perspektiven für Quetiapin in der Behandlung der unipolaren Depression. In: Möller HJ (Hrsg.) Quetiapin. Erfahrungen und Ausblicke. Schattauer GmbH, S. 131-141

Fähser NC, Wiethoff K, Adli M (2005) Therapiealgorithmen in der Langzeitpsychopharmakologie. In: Linden M, Müller WE (Hrsg.) Rehabilitationspsychopharmakologie - Psychopharmakotherapie chronifizierender und chronifizierter Erkrankungen. Köln: Deutscher Ärzteverlag, S. 43-58

Adli M, Wiethoff K (2005). Nicht-pharmakologische Behandlungsstrategien der Depression. In: Bauer M (Hrsg.) Neurobiologie und Therapie bipolarer Erkrankungen. Reihe „Uni-Med Science“. Bremen: Uni-Med, S. 103-121

Berghöfer A, Adli M, Bauer M (2005) Antidepressiva-Übersicht für die klinische Praxis. In: Bauer M, Berghöfer A, Adli M (Hrsg.). Akute und therapieresistente Depressionen. Pharmakotherapie, Psychotherapie, Innovationen. Heidelberg, Berlin, New York: Springer 2005, S. 587-600

Adli M, Wiethoff K, Baghai T, Bauer M (2005). Algorithmusgestützte Behandlung stationärer Patienten mit depressiven Erkrankungen: das Berliner Algorithmusprojekt. In: Bauer M,

Berghöfer A, Adli M (Hrsg). Akute und therapieresistente Depressionen. Pharmakotherapie, Psychotherapie, Innovationen. Heidelberg, Berlin, New York: Springer 2005, S. 477-487
<u>Adli M</u> , Wiethoff K (2004). Nicht-pharmakologische Behandlungsstrategien der Depression. In: Bauer M (Hrsg.) Neurobiologie und Therapie depressiver Erkrankungen. Reihe „Uni-Med Science“. Bremen: Uni-Med, S. 96-112
<u>Adli M</u> , Bauer (2004). M Elektrokonvulsionstherapie bei therapieresistenten Depressionen. In: T. Baghai, R. Frey, S. Kasper, H.-J. Möller (Hrsg.) Elektrokonvulsionstherapie-klinische und wissenschaftliche Aspekte. Wien: Springer, S. 366-393
Berghöfer A, <u>Adli M</u> , Baethge C, Bauer M, Bschor T, Müller-Oerlinghausen B, Schäfer M, Willich SN (2003). Phasenprophylaxe bipolarer Störungen. In: Deutsche Gesellschaft für Bipolare Störungen e.V. (Hrsg.), Erfurth A (Red.): Weißbuch Bipolare Störungen in Deutschland, BoD GmbH, Norderstedt, S. 131-200
Berghöfer A, <u>Adli M</u> , Baethge C, Bauer M, Bschor T, Müller-Oerlinghausen B, Schäfer M, Willich SN (2002). Phasenprophylaxe bipolarer Störungen. In: Deutsche Gesellschaft für Bipolare Störungen e.V. (Hrsg.), Erfurth A (Red.): Kurzfassung Weißbuch Bipolare Störungen in Deutschland, Hamburg, Conference Point, S. 67-74
<u>Adli M</u> , Kießlinger U, Smolka M, Neu P, Linden M, Bauer M (2001). Does algorithm-guided stepwise treatment in depression have an influence on treatment execution? In: Fromm E, ed.: Jahrbuch 2001 des Fachbereichs Humanmedizin der Freien Universität Berlin: S. 466
<u>Adli M</u> , Kießlinger U, Neu P, Smolka M, Linden M, Bauer M (2000). Efficacy of an algorithm-guided treatment regimen in depression compared to standard treatment as usual: The Berlin Algorithm Project. In: Fromm E, ed.: Jahrbuch 2000 des Fachbereichs Humanmedizin der Freien Universität Berlin: S. 439
Kießlinger U, <u>Adli M</u> , Neu P, Smolka M, Linden M, Bauer M (1999). Beschreibung medikamentöser Depressionsbehandlung. In: Jahrbuch 1999, Fachbereich Humanmedizin, Universitätsklinikum Benjamin Franklin der Freien Universität Berlin: S. 494